Related references
Note: Only part of the references are listed.Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study
Austin G. Kulasekararaj et al.
BLOOD (2019)
Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study
Jong Wook Lee et al.
BLOOD (2019)
The renaissance of complement therapeutics
Daniel Ricklin et al.
NATURE REVIEWS NEPHROLOGY (2018)
Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome
Kioa L. Wijnsma et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update
Gianluigi Ardissino et al.
PEDIATRIC NEPHROLOGY (2018)
A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies
Dongfen Yuan et al.
AAPS JOURNAL (2018)
Eculizumab: A Review in Generalized Myasthenia Gravis
Sohita Dhillon
DRUGS (2018)
The impact of eculizumab on routine complement assays
Maria A. Willrich et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2018)
Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action
Douglas Sheridan et al.
PLOS ONE (2018)
Myasthenia gravis: the role of complement at the neuromuscular junction
James F. Howard
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2018)
Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation
Markus J. Harder et al.
BLOOD (2017)
Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders
C. Wehling et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation
Fadi Fakhouri et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment
Johan Vande Walle et al.
JOURNAL OF NEPHROLOGY (2017)
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes
Michela Sica et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Inhibition of complement in Guillain-Barre syndrome: the ICA-GBS study
Amy I. Davidson et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2017)
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Timothy H. J. Goodship et al.
KIDNEY INTERNATIONAL (2017)
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
James F. Howard et al.
LANCET NEUROLOGY (2017)
Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab
Ryan Gately et al.
NEPHROLOGY (2017)
Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence
Savino Sciascia et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Eculizumab for the treatment of hemolytic paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and refractory myasthenia gravis
Joerg Schubert et al.
EXPERT OPINION ON ORPHAN DRUGS (2017)
Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome
Aysegul Oruc et al.
NEFROLOGIA (2017)
Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab
Benedicte Puissant-Lubrano et al.
CLINICAL IMMUNOLOGY (2017)
Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment
E. Volokhina et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab
Ferras Alashkar et al.
ANNALS OF HEMATOLOGY (2017)
Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide
Morag Griffin et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2017)
Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan
Naoko Ito et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2016)
Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation
Dror Mevorach et al.
ANNALS OF NEUROLOGY (2016)
Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation
Sonata Jodele et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field
Johann Castaneda-Sanabria et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan
Haruhiko Ninomiya et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Genetic variants of C5 and polymorphisms of C3 in Chinese patients with paroxysmal nocturnal hemoglobinuria
Y. Du et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2016)
Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway
Janus Asbjorn Schatz-Jakobsen et al.
JOURNAL OF IMMUNOLOGY (2016)
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome
Larry A. Greenbaum et al.
KIDNEY INTERNATIONAL (2016)
Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab
Aude Servais et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey
Fusun Gediz et al.
TRANSFUSION AND APHERESIS SCIENCE (2016)
Update on C3 glomerulopathy
Thomas D. Barbour et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2016)
Eculizumab for Treatment of Rapidly Progressive C3 Glomerulopathy
Moglie Le Quintrec et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Discontinuation of Eculizumab Treatment in Atypical Hemolytic Uremic Syndrome: An Update
Gianluigi Ardissino et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Management of pregnancy in paroxysmal nocturnal hemoglobinuria on long-term eculizumab
Marie-Christiane Vekemans et al.
BLOOD COAGULATION & FIBRINOLYSIS (2015)
Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome
Elena B. Volokhina et al.
CLINICAL IMMUNOLOGY (2015)
Eculizumab in Pediatric Dense Deposit Disease
Michiel J. S. Oosterveld et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort
A. Mallett et al.
INTERNAL MEDICINE JOURNAL (2015)
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
Christoph Licht et al.
KIDNEY INTERNATIONAL (2015)
Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule
Philippe Gatault et al.
MABS (2015)
Atypical aHUS: State of the art
Carla M. Nester et al.
MOLECULAR IMMUNOLOGY (2015)
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria
Richard J. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC
Flore Sicre de Fontbrune et al.
TRANSPLANTATION (2015)
Eculizumab for Treatment of Refractory Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience
B. Yelken et al.
TRANSPLANTATION PROCEEDINGS (2015)
Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab
Regis Peffault de Latour et al.
BLOOD (2015)
Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment
M. Cugno et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Eculizumab hepatotoxicity in pediatric aHUS
Wesley Hayes et al.
PEDIATRIC NEPHROLOGY (2015)
Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy
Sonata Jodele et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults
Sonata Jodele et al.
BLOOD (2014)
Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis
C. Wehling et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab
Yahsou Delmas et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Opportunity Cost of Funding Drugs for Rare Diseases: The Cost-Effectiveness of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Doug Coyle et al.
MEDICAL DECISION MAKING (2014)
Genetic Variants in C5 and Poor Response to Eculizumab
Jun-ichi Nishimura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Systemic Complement Inhibition with Eculizumab for Geographic Atrophy in Age-Related Macular Degeneration
Zohar Yehoshua et al.
OPHTHALMOLOGY (2014)
Efficacy and Safety of Eculizumab in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
Ulrike M. Reiss et al.
PEDIATRIC BLOOD & CANCER (2014)
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
Peter Hillmen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study
Sean J. Pittock et al.
LANCET NEUROLOGY (2013)
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis
James F. Howard et al.
MUSCLE & NERVE (2013)
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome
C. M. Legendre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Eculizumab for Atypical Hemolytic Uremic Syndrome in Pregnancy
Gianluigi Ardissino et al.
OBSTETRICS AND GYNECOLOGY (2013)
Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis
Andrew S. Bomback et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
Julien Zuber et al.
NATURE REVIEWS NEPHROLOGY (2012)
Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolyticuraemic syndrome: an analysis of the German STEC-HUS registry
Jan T. Kielstein et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Eculizumab for the Treatment of Dense-Deposit Disease
Marina Vivarelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Terminal Complement Inhibition Decreases Antibody-Mediated Rejection in Sensitized Renal Transplant Recipients
M. D. Stegall et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival
Richard J. Kelly et al.
BLOOD (2011)
Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena
Alexander Roeth et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
An open label clinical trial of complement inhibition in multifocal motor neuropathy
Amanda M. Fitzpatrick et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2011)
Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab
Richard Kelly et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria
Anita Hill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Ron J. Keizer et al.
CLINICAL PHARMACOKINETICS (2010)
Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria
Joerg Schubert et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
FDA Report: Eculizumab (Soliris (R)) for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
Andrew Dmytrijuk et al.
ONCOLOGIST (2008)
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria
Robert A. Brodsky et al.
BLOOD (2008)
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
BLOOD (2007)
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria
A Hill et al.
BLOOD (2005)
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria
P Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
